Myeloma therapies. A peak into the future

Research output: Contribution to journalArticle

Abstract

Multiple myeloma is a devastating hematologic cancer that is associated with significant comorbidities plaguing the clinical course of the disease. Recent development in myeloma therapeutics has made a positive impact in overall survival of patients. Several new drugs secured approval from the FDA in the last 5 years bringing renewed hope to patients and caregivers. What remains more promising is the combination of these new agents with traditional anti-myeloma therapies that are clinically demonstrating enhanced activity and improvement in the number of patients achieving complete responses. These high rates of clinical responses question the upfront use of high-dose chemotherapy and autologous stem cell transplant. The future of myeloma therapeutics resides in rational and effective combinations that can target both the tumor cell as well as its microenvironment.

Original languageEnglish (US)
Pages (from-to)75-78
Number of pages4
JournalMedicina
Volume67
Issue numberSUPPL. 2
StatePublished - 2007
Externally publishedYes

Fingerprint

Drug Approval
Multiple Myeloma
Caregivers
Comorbidity
Neoplasms
Stem Cells
Therapeutics
Transplants
Drug Therapy
Survival

Keywords

  • Myeloma
  • Treatment

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Myeloma therapies. A peak into the future. / Chanan Khan, Asher A.

In: Medicina, Vol. 67, No. SUPPL. 2, 2007, p. 75-78.

Research output: Contribution to journalArticle

Chanan Khan, AA 2007, 'Myeloma therapies. A peak into the future', Medicina, vol. 67, no. SUPPL. 2, pp. 75-78.
Chanan Khan, Asher A. / Myeloma therapies. A peak into the future. In: Medicina. 2007 ; Vol. 67, No. SUPPL. 2. pp. 75-78.
@article{cb008af5730c415bad58546a86cd66dd,
title = "Myeloma therapies. A peak into the future",
abstract = "Multiple myeloma is a devastating hematologic cancer that is associated with significant comorbidities plaguing the clinical course of the disease. Recent development in myeloma therapeutics has made a positive impact in overall survival of patients. Several new drugs secured approval from the FDA in the last 5 years bringing renewed hope to patients and caregivers. What remains more promising is the combination of these new agents with traditional anti-myeloma therapies that are clinically demonstrating enhanced activity and improvement in the number of patients achieving complete responses. These high rates of clinical responses question the upfront use of high-dose chemotherapy and autologous stem cell transplant. The future of myeloma therapeutics resides in rational and effective combinations that can target both the tumor cell as well as its microenvironment.",
keywords = "Myeloma, Treatment",
author = "{Chanan Khan}, {Asher A}",
year = "2007",
language = "English (US)",
volume = "67",
pages = "75--78",
journal = "Medicina (Argentina)",
issn = "0025-7680",
publisher = "Instituto de Investigaciones Medicas",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Myeloma therapies. A peak into the future

AU - Chanan Khan, Asher A

PY - 2007

Y1 - 2007

N2 - Multiple myeloma is a devastating hematologic cancer that is associated with significant comorbidities plaguing the clinical course of the disease. Recent development in myeloma therapeutics has made a positive impact in overall survival of patients. Several new drugs secured approval from the FDA in the last 5 years bringing renewed hope to patients and caregivers. What remains more promising is the combination of these new agents with traditional anti-myeloma therapies that are clinically demonstrating enhanced activity and improvement in the number of patients achieving complete responses. These high rates of clinical responses question the upfront use of high-dose chemotherapy and autologous stem cell transplant. The future of myeloma therapeutics resides in rational and effective combinations that can target both the tumor cell as well as its microenvironment.

AB - Multiple myeloma is a devastating hematologic cancer that is associated with significant comorbidities plaguing the clinical course of the disease. Recent development in myeloma therapeutics has made a positive impact in overall survival of patients. Several new drugs secured approval from the FDA in the last 5 years bringing renewed hope to patients and caregivers. What remains more promising is the combination of these new agents with traditional anti-myeloma therapies that are clinically demonstrating enhanced activity and improvement in the number of patients achieving complete responses. These high rates of clinical responses question the upfront use of high-dose chemotherapy and autologous stem cell transplant. The future of myeloma therapeutics resides in rational and effective combinations that can target both the tumor cell as well as its microenvironment.

KW - Myeloma

KW - Treatment

UR - http://www.scopus.com/inward/record.url?scp=34548491211&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548491211&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:34548491211

VL - 67

SP - 75

EP - 78

JO - Medicina (Argentina)

JF - Medicina (Argentina)

SN - 0025-7680

IS - SUPPL. 2

ER -